Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Danaher Corporation announced a definitive agreement to purchase GE Life Sciences Biopharma division for approximately $21.4 billion in cash, a business…
Cytiva rises as Danaher completes $21 billion deal, the largest ever acquisition in the bioprocess space, adding the biopharma business unit of GE Healthcare.
Danaher Corporation 10-Q filing reporting the completion of its acquisition of the Biopharma business of GE Healthcare Life Sciences.
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Danaher acquired the Biopharma business of GE Healthcare Life Sciences for $21.4 billion (announced Feb 25, 2019; closed March 31, 2020), the largest acquisition in bioprocessing history. The business was rebranded as Cytiva and became a standalone operating company within Danaher's Life Sciences segment, with ~$3.3 billion in revenue and nearly 7,000 employees at close. To satisfy FTC regulatory conditions, Danaher divested certain affinity/ion-exchange resin, chromatography hardware, biomolecular-characterization and tangential-flow-filtration businesses to Sartorius AG; that sale completed April 30, 2020 for approximately $825 million. The picks-and-shovels thesis has since been validated: in September 2022 Danaher announced merging Cytiva with Pall Corporation's life-sciences business to form a single Biotechnology Group (~$8.5 billion combined revenue, ~$7.5 billion of it bioprocessing), completed in 2023. Cytiva revenue roughly doubled from $3.3 billion to ~$6 billion within a few years of close, and Cytiva tooling now supports the large majority of global monoclonal-antibody manufacturing.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Danaher Corporation / GE Life Sciences Biopharma Business (now Cytiva) (this deal) | 2019 | $21.4B | 76 |
| Danaher Corporation / Pall Corporation | 2015 | $13.6B | 77 |
| Danaher Corporation / Abcam PLC | 2023 | $5.7B | 77 |
| Thermo Fisher Scientific Inc. / Life Technologies Corporation | 2013 | $15.1B | 84 |
| Merck KGaA / Sigma-Aldrich Corporation | 2014 | $17.0B | 80 |
| Becton, Dickinson and Company / C.R. Bard Inc. | 2017 | $24.0B | 77 |
| Johnson & Johnson / Synthes Inc. | 2011 | $19.7B | 77 |
← Browse all deals · How we score deals
More: 2019 deals · Danaher Corporation deals · Multiple (undisclosed) deals